Arcadia Biosciences Q2 FY26 net loss widens 41% to $6.27 million; revenue slips 1% to $1.44 million
RKDA•July Zola sales update
Arcadia said July Zola sales topped $740,000.
First-half results and cash position
First-half net loss attributable to common stockholders widened to $10.65 million from $1.86 million.
Six-month revenue fell 4% to $2.54 million on low inventory balances and longer-than-expected shipping times.
The company ended Q2 with $4.2 million in cash after a $4 million private placement.
Q2 results show wider loss on slightly lower revenue
Arcadia Biosciences posted Q2 net loss attributable to common stockholders of $6.27 million, worsening 41% year over year.
Revenue slipped 1% to $1.44 million, while operating loss narrowed to $496,000 from $501,000.
